Drug class
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitor; oral antihyperglycaemic
Mechanism of action
Inhibits SGLT2 in the proximal renal tubule, reducing reabsorption of filtered glucose and increasing urinary glucose excretion. This lowers blood glucose and also affects intraglomerular haemodynamics and renal/cardiovascular risk pathways.
General use cases
- Glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
- Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
- Reduction of risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death and hospitalisation for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria, under the applicable US label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
